Humacyte
HUMA · Nasdaq · United States
Share price · HUMA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when HUMA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+29.6%
- 15 Oct 2026+24.1%
Nothing announced by HUMA that day or the session before.
- 9 Oct 2026-9.3%
Nothing announced by HUMA that day or the session before.
- 19 Aug 2026+26.3%
- 13 Aug 2026-17.3%
- 23 Jun 2026-16.5%
Nothing announced by HUMA that day or the session before.
- 11 Jun 2026-19.4%
- 13 May 2026+24.2%
- 7 May 2026+9.8%
Nothing announced by HUMA that day or the session before.
- 27 Apr 2026+15.1%
Share of unusual movement by asset
For each asset, the share of HUMA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Human Acellular Vessel (Humacyte)events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 4% |
| Other company news (earnings, financing, releases naming no asset) | — | 36% |
| Sessions with no dated event | — | 59% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | tissue-engineered acellular vascular graftOther | Atherosclerotic Cardiovascular DiseaseVascular TraumaHemodialysis Access |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.0M | $14M | $65M | $16M-$15M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.4M | $18M | $80M | $37M-$22M operating cash flow | report ↗ |
| 2026-Q1 | $0.5M | $19M | $49M | $18M-$25M operating cash flow | report ↗ |
| 2025-Q3 | $0.8M | $17M | $20M | $18M-$24M operating cash flow | report ↗ |
| 2025-Q2 | $0.3M | $22M | $88M | $38M-$26M operating cash flow | report ↗ |
| 2025-Q1 | $0.5M | $15M | $113M | —-$29M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $23M | $71M | $39M-$23M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $24M | $94M | $57M-$21M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $21M | $116M | $32M-$27M operating cash flow | report ↗ |
| 2023-Q3 | — | $19M | $100M+ $0 short-term inv. | $26M-$13M operating cash flow | report ↗ |
| 2023-Q2 | — | $21M | $115M+ $0 short-term inv. | $23M-$23M operating cash flow | report ↗ |
| 2023-Q1 | — | $17M | $130M+ $2.1M short-term inv. | $37M-$19M operating cash flow | report ↗ |
| 2022-Q3 | — | $17M | $164M+ $8.0M short-term inv. | $25M-$17M operating cash flow | report ↗ |
| 2022-Q2 | — | $15M | $181M+ $8.0M short-term inv. | —-$17M operating cash flow | report ↗ |
| 2022-Q1 | — | $16M | $198M+ $8.0M short-term inv. | $20M-$19M operating cash flow | report ↗ |
| 2021-Q3 | — | $15M | $240M | $32M-$59M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.0M | $69M | $51M | $10M-$105M operating cash flow | report ↗ |
Humacyte reported FY2025 revenue of $2.04M, compared with $0M in the prior year. R&D spend was $69.3M, down 21.8% YoY. The company ended the period with $50.85M in cash and equivalents, and reported a net loss of $40.83M, equating to a quarterly net burn of $40.83M.
Operationally, Humacyte continued commercializing Symvess, its FDA-approved acellular tissue engineered vessel for extremity vascular trauma, following the December 2024 approval and 2025 U.S. launch. In dialysis access, the V007 Phase 3 trial met co-primary endpoints, with V012 interim results planned for 2Q26 and a supplemental BLA expected in the second half of 2026. The company also plans a first-in-human CTEV study for coronary bypass in the second half of 2026 and continued preclinical work on the BioVascular Pancreas, with first-in-human studies planned for 2027. Manufacturing capacity is expected to exceed 40,000 ATEVs annually at its existing facility.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $89M | $95M | $37M-$98M operating cash flow | report ↗ |
| 2023-FY | — | $77M | $81M+ $0 short-term inv. | $28M-$73M operating cash flow | report ↗ |
| 2022-FY | — | $63M | $150M+ $2.1M short-term inv. | $3.0M-$71M operating cash flow | report ↗ |
| 2021-FY | — | $61M | $218M+ $8.0M short-term inv. | $6.6M-$81M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 5 purchases ($90K), 2 sales ($82K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-06 | COWARD D SCOTT · director | Award / grant (derivative) | 125,000 | — | — | Form 4 |
| 2026-10-06 | Kuznik Paul Brian · director | Award / grant (derivative) | 125,000 | — | — | Form 4 |
| 2026-09-14 | Jones Keith Anthony · director | Open-market purchase | 10,000 | $0.56 | $6K | Form 4 |
| 2026-08-20 | Jones Keith Anthony · director | Open-market purchase | 10,000 | $0.69 | $7K | Form 4 |
| 2026-08-17 | Jones Keith Anthony · director | Open-market purchase | 30,000 | $0.59 | $18K | Form 4 |
| 2026-06-11 | Dougan Brady W · director | Award / grant (derivative) | 0 | — | — | Form 4 |
| 2026-06-11 | Brown Emery N. · director | Award / grant (derivative) | 80,000 | — | — | Form 4 |
| 2026-06-11 | Bamforth John Philip · director | Award / grant (derivative) | 80,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 157 reporting institutions held 59.0M shares ($35.6M, 21.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 12,316,955 | $7.5M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 7,158,162 | $4.3M |
| 3 | ANTIPODES PARTNERS Ltd | 5,723,750 | $3.5M |
| 4 | GREAT POINT PARTNERS LLC | 3,750,000 | $2.3M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 3,658,108 | $2.2M |
| 6 | STATE STREET CORP | 3,043,929 | $1.8M |
| 7 | UBS Group AG | 2,782,070 | $1.7M |
| 8 | Woodline Partners LP | 2,002,582 | $1.2M |
| 9 | AQR CAPITAL MANAGEMENT LLC | 1,924,691 | $1.2M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,417,825 | $861K |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,291,345 | $783K |
| 12 | NORTHERN TRUST CORP | 1,223,908 | $743K |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,058,048 | $642K |
| 14 | VANGUARD FIDUCIARY TRUST CO | 1,011,029 | $614K |
| 15 | LPL Financial LLC | 864,463 | $524K |